Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Mon ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications and radioactive therapies. The pharmaceutical giants need to focus on specific medical market niches because the Trump administration urges these firms to reduce drug prices and medical costs in America. Pfizer, Merck, and Johnson & Johnson now plan to dramatically reduce headcounts in the next few years. In addition to Pfizer, Merck, Johnson & Johnson, Novartis now plans to cut jobs through early retirement plans and layoffs worldwide. The Swiss pharmaceutical firm Novartis also plans to acquire American cancer drugmaker Endocyte for $2 billion. This strategic move accords with the broader competitive landscape that induces pharmaceutical firms to specialize in new medications and therapies that exhibit low price elasticities of patient demand. In stark contrast to generic prescription drugs, the new therapies and medications require the productive use of medical tech advances and can thus become more effective in treating specific diseases.

In a recent tweet, President Trump condemns pharmaceutical firms such as Pfizer for raising the prices of about 40 prescription drugs. In response, Pfizer CEO Ian Read decides to defer these price hikes to assuage grave concerns about patient demand and consumer protection.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

AYA Analytica podcast provides fresh insights into the latest stock market news, economic trends, and investment portfolio strategies.

Andy Yeh Alpha

2018-12-29 09:32:00 Saturday ET

AYA Analytica podcast provides fresh insights into the latest stock market news, economic trends, and investment portfolio strategies.

Andy Yeh Alpha (AYA) AYA Analytica financial health memo (FHM) podcast channel on YouTube December 2018 AYA Analytica is our online regular podcast and news

+See More

Former Vice President Joe Biden enters the next U.S. presidential race with many moderate policy proposals.

Monica McNeil

2019-05-05 10:34:00 Sunday ET

Former Vice President Joe Biden enters the next U.S. presidential race with many moderate policy proposals.

Former Vice President Joe Biden enters the next U.S. presidential race with many moderate-to-progressive policy proposals. At the age of 76, Biden stands ou

+See More

Fed Chair Jerome Powell hints slower interest rate increases because the current rate is just below the neutral threshold.

Jacob Miramar

2018-12-07 11:35:00 Friday ET

Fed Chair Jerome Powell hints slower interest rate increases because the current rate is just below the neutral threshold.

Fed Chair Jerome Powell hints slower interest rate increases because the current rate is just below the neutral threshold. NYSE and NASDAQ share prices rebo

+See More

The new Brexit deal can boost British pound appreciation and macroeconomic optimism.

Fiona Sydney

2019-11-13 11:34:00 Wednesday ET

The new Brexit deal can boost British pound appreciation and macroeconomic optimism.

The new Brexit deal can boost British pound appreciation and economic optimism. British prime minister Boris Johnson wins the parliamentary vote on his new

+See More

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes.

Apple Boston

2023-03-14 16:43:00 Tuesday ET

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes.

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes. Thomas Pogge and Krishen

+See More

The Trump administration postpones increasing 25% to 30% tariffs on $250 billion Chinese imports after China extends an olive branch to de-escalate Sino-American tariff tension.

Jacob Miramar

2019-10-01 11:33:00 Tuesday ET

The Trump administration postpones increasing 25% to 30% tariffs on $250 billion Chinese imports after China extends an olive branch to de-escalate Sino-American tariff tension.

The Trump administration postpones increasing 25% to 30% tariffs on $250 billion Chinese imports after China extends an olive branch to de-escalate Sino-Ame

+See More